Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib plus ezetimibe lowered LDL nearly 50% vs. placebo in patients with high atherosclerotic risk.

A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...

A strategy that combines high-intensity statin therapy with ezetimibe early after myocardial infarction results in a lower risk of recurrent events when contrasted with approaches that start ...

A combination of simvastatin and ezetimibe (Vytorin) lowered cholesterol better than simvastatin alone, but it had no effect on arterial plaque in a major clinical trial. As a result, cardiologists ...

% differences compared with placebo or indicated statin are based on differences of individual least square means for LDL-C, HDL-C, non-HDL-C and apoB, and on differences of individual medians or ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep, an investigational PCSK9 inhibitor, decreased LDL cholesterol on top of existing oral agents ...

Adding ezetimibe (Zetia) therapy to statins early after a heart attack improved outcomes, Swedish national records suggested. With statins almost universally used in this setting, people who also got ...